Basel ping-pong
Antisoma plc has found a new home for cancer compound AS1404, which Roche passed on last year, as Novartis AG picked up a license in exchange for a hefty upfront fee. Antisoma said the main change since it reacquired the compound is that the data package has significantly evolved.
Antisoma (LSE:ASM, London, U.K.) will get $75 million up front and is eligible for $815 million in milestones, including $380 million related to development, $325 million related to sales and $110 million related to development and sales of an undisclosed backup vascular-targeting agent that is in early development. The partners will develop AS1404 in lung, prostate and ovarian cancer, plus an undisclosed cancer indication and an undisclosed non-oncology indication. ...